Enhanced SLAMF7 homotypic interactions by elotuzumab improves NK cell killing of multiple myeloma

Elotuzumab (Elo) is an IgG(1) monoclonal antibody targeting SLAMF7 (CS1, CRACC, CD319), which is highly expressed on multiple myeloma (MM) cells, natural killer (NK) cells, and subsets of other leukocytes. By engaging with FcγRIIIA (CD16), Elo promotes potent NK cell–mediated antibody-dependent cell...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Immunol Res
Asıl Yazarlar: Pazina, Tatiana, James, Ashley M., Colby, Kimberly B., Yang, Yibin, Gale, Andrew, Jhatakia, Amy, Kearney, Alper Y., Graziano, Robert F., Bezman, Natalie A., Robbins, Michael D., Cohen, Adam D., Campbell, Kerry S.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2019
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6774869/
https://ncbi.nlm.nih.gov/pubmed/31431433
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-18-0579
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller